This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harrison, L. B. Articles by Ramdeen, B. Search for Related Content PubMed PubMed Citation Articles by Harrison, L. B. Articles by Ramdeen, B.

Radiotherapy-Associated Anemia: The Scope of the Problem

Department of Radiation Oncology, Beth Israel Medical Center, St. Luke's-Roosevelt Hospital Center, New York, New York, USA

Correspondence: Louis B. Harrison, M.D., Department of Radiation Oncology, Beth Israel Medical Center, St. Luke's-Roosevelt Hospital Center, 10 Union Square East, New York, New York 10003, USA. Telephone: 212-844-8087; Fax: 212-844-8086; e-mail: lharrison{at}bethisraelny.org

The impact of anemia on cancer patients undergoing chemotherapy is well established, but only recently has the prevalence of anemia in patients receiving radiotherapy received much attention. Many cancer patients present with anemia prior to radiotherapy, and even more experience anemia or a worsening of anemia at some point during treatment. However, the problem of anemia is often ignored because patients may experience only functional anemia, defined as a hemoglobin level less than 12 g/dl. Unless physiologic anemia (hemoglobin = 8 g/dl) is discovered, efforts to correct anemia are often not made. Because hemoglobin levels <12 g/dl seem to be associated with tumor hypoxia and poorer outcomes of radiotherapy in a number of patient populations, ignoring even modest anemia can result in decreased locoregional control, overall survival, and quality of life (QOL). Because increasing hemoglobin levels 1-2 g/dl is usually easily accomplished, there exists the potential for improving outcomes by paying greater attention to this problem. This article focuses on the prevalence of anemia, particularly functional anemia, and discusses the impact of anemia on locoregional control, overall survival, and QOL.

Key Words. Radiotherapy • Anemia • Quality of life • Tumor hypoxia • Locoregional control

This article has been cited by other articles:

				M. S. Aapro Editorial: Anemia Management with Erythropoiesis-Stimulating Agents: A Risk-Benefit Update Oncologist, May 1, 2008; 13(suppl_3): 1 - 3. [Full Text] [PDF]

				A. R. Nissenson, L. T. Goodnough, and R. W. Dubois Anemia: Not Just an Innocent Bystander? Arch Intern Med, June 23, 2003; 163(12): 1400 - 1404. [Full Text] [PDF]